Väinö Lithovius

(please share) Immediate #postdoc job opening in the Millman lab at WashU Med (St. Louis, MO).

Want to develop next-generation pancreatic islets for the study and treatment of diabetes? Email your CV to apply

sites.wustl.edu/millmanlab/

Benchmarking porcine pancreatic ductal organoids for drug screening applications | EMBO Molecular Medicine imageimageState-of-the-art single-cell RNA sequencing and proteomics approaches were employed to benchmark porcine and human pancreatic ductal organoid systems for use as a drug screening and testing ...

Happy to share that our preprint is now published at @embomolmed.org! We expanded on the benchmark of porcine ductal organoids by a pretty extensive proteomics dataset to compare organoids derived from different developmental stages of the pig #devbio #PancSky www.embopress.org/doi/full/10....

7) Thanks to all the coauthors who helped me with this final piece of my PhD. Currently looking for a suitable publication channel!🤓

6) Taken together, relamorelin shows promise as a novel treatment option for CHI, especially when combined with octreotide. Relamorelin has been found to be well tolerated in adult diabetes patients, suggesting it could be repurposed for CHI, which is still difficult to manage for modern medicine

5) We then investigated a long-acting analogue of ghrelin, relamorelin in combination with octreotide, the current first line treatment for these CHI patients. We demonstrate that the combination of these drugs act synergistically to increase blood glucose more than the sum of the individual drugs

4) In these mice, we tested ghrelin, which reversed the hypoglycaemia and reduced the human SC-islet specific insulin secretion

3) we then implanted immunocompromised mice with KCNJ11 wildtype and knockout SC-islets, demonstrating rapid development of hyperinsulinaemic hypoglycaemia in the mice implanted with the knockout SC-islets

2) We then tested insulin secretion affecting compounds in vitro for their ability to suppress the insulin hypersecretion from the KCNJ11 knockout SC-islets. We identified the expected reduction from the clinically used octreotide and exendin 9-39 with reduction with 3 novel compounds

1) We created KCNJ11 knockout stem cells, differentiated them to stem cell derived islets (SC-islets) and demonstrated over 3-fold increased insulin secretion in sub-stimulatory glucose, recapitulating the cardinal defect of congenital hyperinsulinism in vitro

Reporting on successful use of SC-islets in drug development for #congenitalhyperinsulinism! We identified ghrelin analogues as novel candidate drugs, demonstrating reversal of hypoglycaemia in mice, which was caused by the hyperinsulinaemic human SC-islets #PancSky www.biorxiv.org/content/10.1...

Ghrelin and relamorelin alleviate hypoglycaemia in humanised mice with congenital hyperinsulinism KATP-channel related hyperinsulinism (KATPHI) is a genetic disorder of the pancreatic beta cells, manifesting as life-threatening hypoglycaemia in neonates due to dysregulated insulin secretion. Manag...

Great work from my friend @lithoviusv.bsky.social with very nice combination of disease modeling and a drug gable solution to pair it with! @PancSky www.biorxiv.org/content/10.1...

Ghrelin and relamorelin alleviate hypoglycaemia in humanised mice with congenital hyperinsulinism https://www.biorxiv.org/content/10.1101/2025.10.02.680116v1

Benchmarking porcine pancreatic ductal organoids for drug screening applications Primary human pancreatic ductal organoids (HPDO) have emerged as a model to study pancreas biology and disease. Yet, donor material availability, and a lack of extensive benchmarking limits the range ...

Happy to share our work on pancreatic ductal organoids from the human-relevant pig model across developmental stages ranging from embryonic to adult animals and using them for drug screening applications from the @heikolickert.bsky.social lab. #PancSky #devbio 🧪🧬 www.biorxiv.org/content/10.1... /1

Postdoctoral Research Fellow - Vancouver, British Columbia (CA) job with University of British Columbia Department of Surgery | 12837375 The successful candidate will work on a project developing cell-based therapies for those living with type 1 diabetes (T1D).

We're looking for postdoctoral scholars to join our team in Vancouver 🇨🇦. We work on cell-based approaches aimed at curing type 1 diabetes. Bring your own ideas for projects or work on one that's already funded! More details here: www.nature.com/naturecareer...

Come listen to the superb speakers on session 5 of #EISG2025 - Modelling Human Islet Cell Devt :

- Francesca Spagnoli (@labspagnoli.bsky.social, Kings College London)
- Diego Balboa (@diegobalboa.bsky.social , @helsinkiuni.bsky.social)
- Limor Landsman (Tel Aviv U.)

Register now at eisg2025.se

Let's take a look at the amazing invited speakers at #EISG2025, shall we?

On Session 1 we will hear all about genomics of islet cells from:

Amélie Bonnefond (INSERM/CNRS),
Rohit Kulkarni (Harvard U.), and
Torben Hansen (U. of Copenhagen)

Register now at eisg2025.se
(Early bird until 13 March)

PhD student in regeneration of insulin-producing beta-cells in diabetes models - Uppsala University PhD student in regeneration of insulin-producing beta-cells in diabetes models, Institutionen för medicinsk cellbiologi, Uppsala University

Fancy joining our lab? apply here for a PhD student position, (DM me for potential postdoc opportunities)
www.uu.se/en/about-uu/...

Inceptor binds to and directs insulin towards lysosomal degradation in β cells - Nature Metabolism The insulin inhibitory receptor (inceptor) is found to bind to insulin and to regulate insulin stores by directing proinsulin and insulin towards lysosomal degradation.

Thrilled to share one of our biggest discoveries: “Inceptor binds to and directs insulin towards lysosomal degradation in beta cells”.
doi.org/10.1038/s422...
A tremendous collaborative effort led by JohannaSiehler, Sara Bilekova and other members of the Lickert lab @heikolickert.bsky.social